PROLIFICA

Prevention of Liver Fibrosis and Cancer in Africa

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +44 207 594 3866 Fax: +44 207 594 3868
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://prolifica.eu/
Totale costo	4˙781˙843 €
EC contributo	3˙000˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-AFRICA-2010
Funding Scheme	CP-FP-SICA
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-02-01   -   2016-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +44 207 594 3866 Fax: +44 207 594 3868	UK (LONDON)	coordinator	642˙000.00
2	MEDICAL RESEARCH COUNCIL  Organization address address: NORTH STAR AVENUE POLARIS HOUSE city: SWINDON postcode: SN2 1FL contact info Titolo: Prof. Nome: Tumani Cognome: Corrah Email: send email Telefono: +220 4496715 Fax: +220 4494154	UK (SWINDON)	participant	1˙105˙300.00
3	UNIVERSITE CHEIKH ANTA DIOP DE DAKAR  Organization address address: Avenue Martin Luther King city: DAKAR FANN postcode: - contact info Titolo: Prof. Nome: Souleymane Cognome: Mboup Email: send email Telefono: +221 338216420 Fax: +221 338216422	SN (DAKAR FANN)	participant	324˙000.00
4	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER  Organization address address: Cours Albert-Thomas 150 city: LYON CEDEX 08 postcode: 69372 contact info Titolo: Dr. Nome: Olaf Cognome: Kelm Email: send email Telefono: +33 4 72738494 Fax: +33 4 72738564	FR (LYON CEDEX 08)	participant	236˙000.00
5	XEPTAGEN SPA  Organization address address: Via delle Industrie 9 city: VENEZIA postcode: 30175 contact info Titolo: Dr. Nome: Giorgio Cognome: Fassina Email: send email Telefono: 390415000000 Fax: 390415000000	IT (VENEZIA)	participant	208˙000.00
6	JOS UNIVERSITY TEACHING HOSPITAL  Organization address address: MURTALA MOHAMMED WAY PLATEAU STATE city: JOS postcode: 930001 contact info Titolo: Dr. Nome: Edith Cognome: Okeke Email: send email Telefono: 2348040000000 Fax: 2348040000000	NG (JOS)	participant	189˙500.00
7	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Ms. Nome: Hiba Cognome: Vergnaud Email: send email Telefono: +33 4 72 13 88 39 Fax: +33 4 72 13 88 01	FR (PARIS)	participant	158˙000.00
8	Ministry of Health and Social Welfare  Organization address address: "The quadrangle, Banjul" city: Banjul contact info Titolo: Dr. Nome: Makie Cognome: Taal Email: send email Telefono: +220 3908808	GM (Banjul)	participant	137˙200.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Chronic hepatitis B virus (HBV) infection affects 350 million people worldwide and 25-30% of these individuals will die as a result of their infection mainly as a results of hepatocellular carcinoma HCC. Liver cirrhosis, high viral load and dietary exposure to aflatoxin are recognised as risk factors for hepatocellular carcinoma amongst HBV carriers. However, these variables do not account for all cases of HCC and decompensated cirrhosis is rarely ever seen in West Africa suggesting that advanced liver fibrosis may not be an important risk factor in this population. A large case control study on HCC will be used to evaluate the importance of liver fibrosis and other established risk factors in West Africa and to explore other potential oncogenic determinants. The case-control study will generate serum, urine and DNA samples for proteomic, metabonomic and genomic analysis to identify biomarkers and aetiological agents for HCC. Effective treatment for HBV infection is now available in the developed world but treatment programmes have not been developed for resource poor settings even though some of the effective medication is now available at low cost for HIV management. A trial of HBV treatment in a group of carefully selected high risk patients will be conducted to demonstrate that the incidence of HCC can be reduced in this population as has been observed in Asian patients. The treatment trial will also be used to evaluate the efficacy of screening by ultrasound for early tumours which can be treated with percutaneous alcohol injection. This comprehensive programme therefore aims to reveal novel aetiological factors for HCC, identify and evaluate biomarkers and demonstrate the efficacy of selective antiviral therapy to prevent HCC'

Introduzione (Teaser)

Chronic hepatitis B virus (HBV) often results in a common form of liver cancer, hepatocellular carcinoma (HCC). A large-scale case study in West Africa aims to improve screening and treatment of HBV and HCC, as well as reduce the incidence of liver cancer.